Given that roughly half of advanced MCC patients do not respond to PD-1/PD-L1 monotherapy [6], researchers are investigating whether combination approaches can enhance immunotherapeutic efficacy or overcome resistance. This evidence concerns the gene CD274 and Merkel cell skin cancer.